Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment

Basit Öğe Kaydı
dc.authorid0000-0003-1944-2477
dc.authorid0000-0001-8674-2141
dc.authorid0000-0001-8518-4598
dc.authorid0000-0002-2540-2060
dc.authorid0000-0002-1706-230X
dc.authorid0000-0002-3123-0963
dc.authorid0000-0002-4151-5903
dc.contributor.authorTahmaz, Alper
dc.contributor.authorDikmen, Merve Yildiz
dc.contributor.authorYildirim, Figen
dc.contributor.authorKaygusuz, Turkkan Ozturk
dc.contributor.authorKarabay, Oguz
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorAlkan, Sevil
dc.date.accessioned2026-02-03T11:59:48Z
dc.date.available2026-02-03T11:59:48Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIn this multicenter, retrospective study involving 62 patients, we investigated whether switching from entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) represents a superior treatment strategy for patients with chronic hepatitis B (CHB) experiencing low-level viremia (LLV). The study determined that TAF significantly improved both virological and biochemical outcomes. At 48 weeks, the complete virological response (CVR) rate was 77.8% for those who switched from ETV and 81.8% for those who switched from TDF, with Hepatitis B virus deoxyribonucleic acid (HBV DNA) negativity reaching 81% by month 12. Additionally, significant normalization of liver enzymes, albumin, and platelet counts was observed across the cohort. While the switch from TDF was associated with a significant increase in triglycerides and high-density lipoprotein (HDL) and a decrease in estimated glomerular filtration rate (eGFR), no such changes were detected in the ETV group. This evidence suggests that TAF provides robust virological control in LLV patients and is associated with favorable biochemical improvements. However, due to the study's limitations, the strong assertion that TAF promotes the regression of liver fibrosis and reduces the risk of hepatocellular carcinoma (HCC) must be interpreted with caution.
dc.description.sponsorshipArticle Processing Charge (APC)
dc.description.sponsorshipThis work was supported by the Article Processing Charge (APC) for the manuscript, which was sponsored by Drogsan & Idot;laclar & imath; San. ve Tic. A.& Scedil;. No other external funding was received for this research.
dc.identifier.doi10.3390/v17111471
dc.identifier.issn1999-4915
dc.identifier.issue11
dc.identifier.pmid41305493
dc.identifier.urihttps://doi.org/10.3390/v17111471
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34425
dc.identifier.volume17
dc.identifier.wosWOS:001624669700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofViruses-Basel
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260130
dc.subjectlow level viremi
dc.subjectHepatitis B
dc.subjecttenofovir
dc.subjecttenofovir alafenamide (TAF)
dc.subjectentecavir
dc.subjectefficiency
dc.subjecthepatocellular carcinoma
dc.titleEvaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu